Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Patients’ Genes Could Hold Clue to Reducing Severe Sepsis

By University of Queensland | August 4, 2016

1000 blood samples to create a world leading genomics resource. Source: University of Queensland

Patients’ genes could unlock urgently needed new treatments for severe sepsis, which kills three and a half times as many Australians as the road toll.

Researchers from The University of QueenslandDiamantina Institute and the George Institute for Global Health, Sydney, are investigating whether genetic variation between critically-ill patients contributes to their susceptibility to bacterial infection, the severity of their disease and their response to treatment.

Researcher Professor David Evans said researchers would analyse up to 1000 blood samples, creating a world-leading genomics resource to help develop new treatments for severe sepsis, including the possibility of personalised therapies.

“Severe sepsis remains a major cause of mortality and disability worldwide and we are working closely with an extensive network of clinical collaborators on this project,” Professor Evans said.

Samples will be collected from patients from 25 sites in Australia and New Zealand and will be analysed at the UQ Diamantina Institute.

In Australia there are more than 15,000 new cases of severe sepsis in the adult population each year, and approximately one in three adults admitted to hospital with the condition die within 28 days.

“The cause of death is most commonly due to multiple-organ failure,” Professor Evans said. 

“By undertaking this study we hope to develop a model to predict 90 day mortality in sepsis patients, and determine which patients are likely to respond to a particular treatment.”

The study is running alongside a major randomised clinical trial of hydrocortisone therapy for severe sepsis patients.

The clinical trial, known as ‘ADRENAL’ is being led by intensive care specialist at the Wesley and Princess Alexandra Hospitals, Professor Bala Venkatesh.

Professor Venkatesh said there have previously been more than 70 research trials in the past two decades into new treatments for sepsis but the results have been disappointing.

“Two major trials have produced conflicting results, so there is now no consensus as to the use of hydrocortisone and there is a strong view this discrepancy reflects individual differences.

“It may be that corticosteroids would benefit some patients but could harm others, and the study led by Professor Evans could determine who will respond based on their genomic profile.”

Sample collection for the genome trial will continue into next year, with results expected in 2018.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

DNA Script SYNTAX
DNA Script raises $165M Series C for DNA printing platform
DNA Script SYNTAX
DNA Script launches a benchtop DNA printer
DNA
Unraveling the promise of genetics for treating progressive illness 
Alzheimer's disease
How to build a foundation for the next phase of Alzheimer’s disease research

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50